CD8A and metabolic dysfunction-associated steatotic liver disease: The combination of anti-PD-1 and STM2457 treatment also markedly increased the levels of IFN-γ + and Granzyme B + CD8 + T cells in NAFLD-HCC tumors and exhibited synergistic inhibition of tumor growth in syngeneic orthotopic NAFLD-HCC models [139].